`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE SOUTHERN DISTRICT OF INDIANA
`INDIANAPOLIS DIVISION
`
`Plaintiff,
`
`v.
`
`ELI LILLY AND COMPANY,
`
`
`
`
`
`FRESENIUS KABI USA, LLC,
`
`
`
`
`Defendant.
`
`)
`)
`)
` )
` ) Civil Action No. 1:16-cv-2960
` )
` )
` )
` )
` )
`
`COMPLAINT
`
`Plaintiff Eli Lilly and Company (“Lilly”), by its attorneys, hereby alleges as
`
`follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for patent infringement under the patent laws of the
`
`United States, Title 35, United States Code, that arises out of the filing by defendant Fresenius
`
`Kabi USA, LLC (“Fresenius”) of an Abbreviated New Drug Application (“ANDA”) with the
`
`U.S. Food and Drug Administration (“FDA”) seeking approval to manufacture and sell its
`
`Pemetrexed Disodium for Injection, Eq. 750 mg Base/Vial product (“Fresenius’s ANDA
`
`Product”) prior to the expiration of U.S. Patent No. 7,772,209 (“the ’209 patent”). Fresenius
`
`notified Lilly that it had submitted to the FDA an amendment to ANDA No. 90-384, seeking
`
`approval for Fresenius’s ANDA Product, by letter dated October 6, 2016 (“Fresenius’s Notice
`
`Letter” or “Notice Letter”). Upon information and belief, Fresenius’s ANDA Product will be
`
`marketed as a generic version of ALIMTA®, a chemotherapy agent developed and distributed by
`
`Lilly and used for the treatment of various types of cancer.
`
`
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 2 of 8 PageID #: 2
`
`
`
`PARTIES
`
`2.
`
`Lilly is a corporation organized and existing under the laws of the State of
`
`Indiana, having its corporate offices and place of business at Lilly Corporate Center,
`
`Indianapolis, Indiana 46285.
`
`3.
`
`Upon information and belief, Fresenius is a corporation organized and
`
`existing under the laws of the State of Delaware, having a principal place of business at 3
`
`Corporate Drive, Lake Zurich, Illinois 60047. Upon information and belief, Fresenius is in the
`
`business of manufacturing, marketing, and selling generic drug products. Upon information and
`
`belief, Fresenius was formerly known as APP Pharmaceuticals, LLC.
`
`JURISDICTION AND VENUE
`
`4.
`
`This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331,
`
`1338(a), 2201, and 2202.
`
`5.
`
`6.
`
`Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400(b).
`
`This Court has personal jurisdiction over Fresenius because, upon
`
`information and belief: (1) Fresenius is in the business of manufacturing products which it and/or
`
`its affiliates or subsidiaries distribute, sell, and offer to sell throughout the United States,
`
`including Indiana and the Southern District of Indiana; (2) Fresenius derives substantial revenue
`
`from things sold, used, or consumed within Indiana and the Southern District of Indiana; (3) as
`
`part of its ordinary business practice of engaging in U.S. patent litigation, Fresenius litigated
`
`ANDA cases in this District, including by asserting counterclaims; (4) following any FDA
`
`approval of ANDA No. 90-384 Fresenius intends to distribute (directly and/or through affiliates
`
`or subsidiaries) Fresenius’s ANDA Product within Indiana and this District; (5) Fresenius
`
`knowingly and purposefully directed Fresenius’s Notice Letter to Lilly at its principal place of
`
`
`
`2
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 3 of 8 PageID #: 3
`
`
`
`business within this District, thus intentionally challenging the intellectual property rights held
`
`by an Indiana corporation in this District; (6) if Fresenius is permitted to sell Fresenius’s ANDA
`
`Product in the United States prior to the expiration of the ’209 patent, Fresenius will cause
`
`substantial injury to Lilly, an Indiana corporation headquartered within the Southern District of
`
`Indiana, and Fresenius knows that Lilly will be injured by such actions in Indiana and this
`
`District; and (7) directly and/or through its affiliates or subsidiaries, Fresenius regularly does and
`
`solicits business in Indiana and this District, including the distribution and sale of drug products
`
`in Indiana and this District; is engaged in and has maintained systematic and continuous business
`
`contacts within the State of Indiana and this District; and has purposefully availed itself of the
`
`benefits and protections of the laws of Indiana. In addition, Lilly was in litigation in this Court
`
`with Fresenius (including under its former name of APP Pharmaceuticals, LLC) regarding the
`
`same ANDA No. 90-384, in Case Nos. 1:10-cv-1376-TWP-DKL and 1:15-cv-96-TWP-DKL
`
`(now consolidated with Case No. 1:10-cv-1376), and Fresenius did not challenge personal
`
`jurisdiction in those actions. Case No. 1:10-cv-1376 is currently on appeal to the Federal Circuit,
`
`Case No. 2015-2067.
`
`BACKGROUND
`
`7.
`
`ALIMTA® is indicated (in combination with cisplatin) (a) for the
`
`treatment of patients with malignant pleural mesothelioma, or (b) for the initial treatment of
`
`locally advanced or metastatic nonsquamous non-small cell lung cancer. ALIMTA® also is
`
`indicated as a single-agent for the treatment of patients with locally advanced or metastatic
`
`nonsquamous non-small cell lung cancer after prior chemotherapy. ALIMTA® also is indicated
`
`for maintenance treatment of patients with locally advanced or metastatic nonsquamous non-
`
`
`
`3
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 4 of 8 PageID #: 4
`
`
`
`small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-
`
`line chemotherapy.
`
`8.
`
`Lilly sells ALIMTA® in the United States pursuant to a New Drug
`
`Application that has been approved by the FDA.
`
`9.
`
`The ’209 patent, titled “Antifolate Combination Therapies,” was duly and
`
`legally issued on August 10, 2010. The ’209 patent is attached as Exhibit A.
`
`10.
`
`Lilly is the assignee of the ’209 patent. As set forth in greater detail in the
`
`’209 patent, one or more claims of the ’209 patent, incorporated by reference herein, cover a
`
`method of administering pemetrexed disodium to a patient in need thereof that also involves
`
`administration of folic acid and vitamin B12.
`
`11.
`
`Lilly has previously asserted the ’209 patent against Fresenius (including
`
`under its former name of APP Pharmaceuticals, LLC) in this Court, alleging, inter alia, that the
`
`filing of ANDA No. 90-384, seeking FDA approval for 100 mg Base/Vial, 500 mg Base/Vial,
`
`and 1000 mg Base/Vial ANDA products, infringed the ’209 patent. These actions were before
`
`this Court as Case Nos. 10-cv-1376-TWP-DKL and 1:15-cv-96-TWP-DKL (now consolidated
`
`with Case No. 1:10-cv-1376), and Case No. 1:10-cv-1376 is currently on appeal to the Federal
`
`Circuit, Case No. 2015-2067. The instant action concerns an amendment to the same ANDA No.
`
`90-384, seeking FDA approval for a 750 mg Base/Vial product.
`
`12.
`
`An actual case or controversy exists between Lilly and Fresenius with
`
`respect to infringement of the ’209 patent.
`
`13.
`
`This action is being filed within 45 days of Lilly’s receipt of Fresenius’s
`
`Notice Letter.
`
`
`
`4
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 5 of 8 PageID #: 5
`
`
`
`herein.
`
`COUNT
`
`(Infringement of U.S. Patent No. 7,772,209)
`
`14.
`
`Lilly incorporates each of the preceding paragraphs as if fully set forth
`
`15.
`
`Upon information and belief, Fresenius’s ANDA Product contains
`
`pemetrexed disodium.
`
`16.
`
`Upon information and belief, the use of Fresenius’s ANDA Product in
`
`accordance with Fresenius’s proposed labeling for Fresenius’s ANDA Product involves
`
`administration of folic acid and vitamin B12.
`
`17.
`
`Upon information and belief, the use of Fresenius’s ANDA Product in
`
`accordance with and as directed by Fresenius’s proposed labeling for that product will infringe
`
`one or more claims of the ’209 patent.
`
`18.
`
`Upon information and belief, Fresenius filed as a part of ANDA No. 90-
`
`384 a certification of the type described in Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), asserting that the claims of the ’209 patent are invalid and/or not
`
`infringed by the manufacture, use, offer for sale, or sale of Fresenius’s ANDA Product.
`
`19.
`
`The purpose of ANDA No. 90-384 was to obtain approval under the
`
`FDCA to engage in the commercial manufacture, use, offer for sale, and/or sale of Fresenius’s
`
`ANDA Product prior to the expiration of the ’209 patent.
`
`20.
`
`Fresenius’s submission of ANDA No. 90-384 for the purpose of obtaining
`
`approval to engage in the commercial manufacture, use, offer for sale, and/or sale of Fresenius’s
`
`ANDA Product prior to the expiration of the ’209 patent is an act of infringement of the ’209
`
`patent under 35 U.S.C. § 271(e)(2)(A).
`
`
`
`5
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 6 of 8 PageID #: 6
`
`
`
`21.
`
`Upon information and belief, Fresenius intends to engage in the
`
`manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of Fresenius’s
`
`ANDA Product and the proposed labeling therefor immediately and imminently upon approval
`
`of ANDA No. 90-384, i.e., prior to the expiration of the ’209 patent.
`
`22.
`
`Upon information and belief, Fresenius has knowledge of the claims of the
`
`’209 patent. Notwithstanding this knowledge, Fresenius has continued to assert its intent to
`
`engage in the manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of
`
`Fresenius’s ANDA Product and the proposed labeling therefor immediately and imminently
`
`upon approval of ANDA No. 90-384.
`
`23.
`
`Upon information and belief, Fresenius plans and intends to, and will,
`
`actively induce infringement of the ’209 patent when its ANDA is approved, and plans and
`
`intends to, and will, do so immediately and imminently upon approval.
`
`24.
`
`Upon information and belief, Fresenius knows that Fresenius’s ANDA
`
`Product is especially made or adapted for use in infringing the ’209 patent, and that Fresenius’s
`
`ANDA Product is not suitable for substantial noninfringing use. Upon information and belief,
`
`Fresenius plans and intends to, and will, contribute to infringement of the ’209 patent
`
`immediately and imminently upon approval of ANDA No. 90-384.
`
`25.
`
`The foregoing actions by Fresenius constitute and/or will constitute
`
`infringement of the ’209 patent, active inducement of infringement of the ’209 patent, and
`
`contribution to the infringement by others of the ’209 patent.
`
`26.
`
`In Case No. 10-cv-1376-TWP-DKL, this Court rejected Fresenius’s
`
`challenges to the validity of certain claims of the ’209 patent as well as its non-infringement
`
`defenses. Accordingly, Fresenius is estopped from challenging the validity of those claims of the
`
`
`
`6
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 7 of 8 PageID #: 7
`
`
`
`’209 patent in this case. In addition, because, on information and belief, Fresenius’s ANDA
`
`Product is the substantially same as the products that were the subject of Case No. 10-cv-1376-
`
`TWP-DKL other than the quantity of pemetrexed disodium in each vial, which is irrelevant to
`
`whether Fresenius has infringed or will infringe the ’209 patent, Fresenius also is estopped from
`
`contesting infringement.
`
`27.
`
`Upon information and belief, Fresenius is without a reasonable basis for
`
`believing that it will not be liable for infringing the ’209 patent, actively inducing infringement
`
`of the ’209 patent, and/or contributing to the infringement by others of the ’209 patent.
`
`28.
`
`Unless Fresenius is enjoined from infringing the ’209 patent, actively
`
`inducing infringement of the ’209 patent, and contributing to the infringement by others of the
`
`’209 patent, Lilly will suffer irreparable injury. Lilly has no adequate remedy at law.
`
`WHEREFORE, Lilly requests the following relief:
`
`(a)
`
`A judgment that Fresenius has infringed the ’209 patent and/or will
`
`infringe, actively induce infringement of, and/or contribute to infringement by others of the ’209
`
`patent;
`
`(b)
`
`A judgment ordering that the effective date of any FDA approval for
`
`Fresenius to make, use, offer for sale, sell, market, distribute, or import Fresenius’s ANDA
`
`Product, or any product the use of which infringes the ’209 patent, be not earlier than the
`
`expiration date of the ’209 patent, inclusive of any extension(s) and additional period(s) of
`
`exclusivity;
`
`(c)
`
`A preliminary and permanent injunction enjoining Fresenius, and all
`
`persons acting in concert with Fresenius, from making, using, selling, offering for sale,
`
`marketing, distributing, or importing Fresenius’s ANDA Product, or any product the use of
`
`
`
`7
`
`
`
`Case 1:16-cv-02960-TWP-DKL Document 1 Filed 11/01/16 Page 8 of 8 PageID #: 8
`
`
`
`which infringes the ’209 patent, or the inducement of or contribution to any of the foregoing,
`
`prior to the expiration date of the ’209 patent, inclusive of any extension(s) and additional
`
`period(s) of exclusivity;
`
`(d)
`
`A judgment declaring that making, using, selling, offering for sale,
`
`marketing, distributing, or importing of Fresenius’s ANDA Product, or any product the use of
`
`which infringes the ’209 patent, prior to the expiration date of the ’209 patent, infringes, will
`
`infringe, will actively induce infringement of, and/or will contribute to the infringement by
`
`others of the ’209 patent;
`
`(e)
`
`A declaration that this is an exceptional case and an award of attorneys’
`
`fees pursuant to 35 U.S.C. § 285;
`
`(f)
`
`(g)
`
`An award of Lilly’s costs and expenses in this action; and
`
`Such further and other relief as this Court may deem just and proper.
`
`Dated: November 1, 2016
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`/s/ Jan M. Carroll
`
`Jan M. Carroll, No. 4187-49
`Anne N. DePrez, No. 4728-49
`Barnes & Thornburg LLP
`11 South Meridian Street
`Indianapolis, IN 46220
`Telephone: 317-236-1313
`Facsimile: 317-231-7443
`jan.carroll@btlaw.com
`anne.deprez@btlaw.com
`
`Attorneys for Plaintiff
`Eli Lilly and Company
`
`
`
`
`8
`
`DMS 4450041v1
`
`
`
`